Working... Menu
Trial record 20 of 245 for:    "ottawa heart institute"

Biomarkers to Classify Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02347722
Recruitment Status : Active, not recruiting
First Posted : January 27, 2015
Last Update Posted : January 7, 2019
Genome Canada
Roche Diagnostics
Information provided by (Responsible Party):
Peter Liu, Ottawa Heart Institute Research Corporation

Brief Summary:
The purpose of this study is to evaluate existing biomarkers and see if they can be used to accurately diagnose the etiology of heart failure.

Condition or disease
Heart Failure

Detailed Description:

This is a cohort study consisting of 2 patient cohorts. The first cohort will be studied retrospectively, using existing blood samples from different biobanks. Biomarkers will be measured and matched with the etiology of previously diagnosed heart failure by a biomarker panel of heart failure experts. This cohort consists of 100 patients each with (1) ischemic cardiomyopathy, (2) dilated cardiomyopathy and (3) diastolic heart failure. Blood samples will be analyzed for novel biomarkers. Investigators will be seeking biomarker candidate(s) alone or in combination which can predict each category of heart failure etiology with over 85% accuracy and the lowest levels of reclassification. A panel of heart failure experts will be assembled, and the appropriate cut-off values determined. Once this goal has been achieved, the prospective study will go ahead.

In the second cohort, biomarkers will be measured and used to diagnose the etiology of heart failure for each subject. This diagnosis will then be compared to the diagnosis from results of the usual diagnostic tests. Investigators will recruit 450 patients admitted to hospital or outpatient clinics with recently diagnosed heart failure (<2 years) and test for different biomarkers. Using the biomarker values, investigators will predict their heart failure etiology in an objective manner. The patients will then undergo definitive etiological workup as usual to establish the actual etiology of the heart failure. The duration of a typical etiological workup is about 3 days for hospitalized patients and up to 8 weeks for patients admitted to outpatient clinics. The predictive accuracy of the new heart failure panel will be compared to clinical assessment.

Investigators will perform cost-modeling in terms of the potential savings in avoiding unnecessary coronary angiographies or perfusion scans in a typical mixed cohort of heart failure patients based on the marker determined etiology.

A group of healthy volunteers will be added. This group will serve as age matched controls to the prospective cohort of heart failure patients.

Layout table for study information
Study Type : Observational
Actual Enrollment : 511 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Evaluation of Existing Biomarker Candidates to Accurately Classify the Etiology of Heart Failure
Study Start Date : May 2015
Actual Primary Completion Date : December 2018
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
Healthy volunteers
Age matched healthy volunteers for comparison with heart failure patients

Primary Outcome Measures :
  1. Accuracy of heart failure panel to predict etiology of heart failure using biomarkers. [ Time Frame: at end of study ]

Secondary Outcome Measures :
  1. cost savings [ Time Frame: At end of study ]

Biospecimen Retention:   Samples Without DNA
Serum and plasma for biomarkers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The retrospective cohort consists of stored blood samples from various biobanks.

The prospective cohort consists of patients admitted to academic hospitals or outpatient clinics with symptomatic heart failure diagnosed within 2 years.

The volunteer cohort consists of age matched healthy volunteers


Inclusion Criteria:

  • Patients admitted with symptomatic heart failure, diagnosed within 2 years.
  • Diagnosis of congestive heart failure using the modified Framingham criteria:

Simultaneous presence of at least 2 major criteria or 1 major criterion in conjunction with 2 minor criteria or a previous clear diagnosis of heart failure.

Major criteria:

  • Paroxysmal nocturnal dyspnea or orthopnea
  • Neck vein distention
  • Rales/Crackles (>10 cm from base of lungs)
  • Acute pulmonary edema
  • S3 gallop
  • Increased central venous pressure (>16 cm H2O at right atrium)
  • Hepatojugular reflux
  • Weight loss >4.5 kg in 5 days in response to treatment Echocardiographic left ventricular dysfunction

Minor criteria:

  • Bilateral ankle edema
  • Nocturnal cough
  • Dyspnea on exertion
  • Hepatomegaly
  • Pleural effusion
  • Weight loss >4.5 kg caused by heart failure where factors other than treatment of CHF could have contributed to the weight loss
  • Tachycardia (heart rate >120 beats/min) Minor criteria are acceptable only if they cannot be attributed to another medical condition (such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome).

Exclusion Criteria:

  • Patients unable to provide blood sample
  • Patients unable to provide consent
  • Patient with life expectancy of less than 6 months, or has major co-morbidities.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
  • Participants who have participated in another research trial involving an investigational product in the past 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02347722

Layout table for location information
Canada, Ontario
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Genome Canada
Roche Diagnostics
Layout table for investigator information
Principal Investigator: Peter Liu, MSc, MD Ottawa Heart Institute Research Corporation

Layout table for additonal information
Responsible Party: Peter Liu, Chief Scientific Officer and VP of Research, Ottawa Heart Institute Research Corporation Identifier: NCT02347722     History of Changes
Other Study ID Numbers: 2014869-01H
First Posted: January 27, 2015    Key Record Dates
Last Update Posted: January 7, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data will be presented as the mean and standard deviation for the main cohort and sub-groups.

Keywords provided by Peter Liu, Ottawa Heart Institute Research Corporation:
etiology of heart failure

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases